<DOC>
	<DOCNO>NCT01920893</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy dupilumab ( SAR231893 / REGN668 ) treatment bilateral Nasal Polyposis ( NP ) assessment endoscopic nasal polyp score comparison placebo . Secondary Objectives : To evaluate effect dupilumab regard : - symptom sinusitis - sinus Computed Tomography ( CT ) scan - nasal polyp score sub-group patient co-morbid asthma - Safety tolerability</brief_summary>
	<brief_title>An Evaluation Dupilumab Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis</brief_title>
	<detailed_description>Screening period ( 4 week ) + Randomized Treatment Period ( 16 week ) + Post-Treatment Period ( 16 week ) = 36 week . To ensure least 28 patient co-morbid asthma need subgroup analysis , recruitment NP patient without co-morbid asthma stop approximately 28 patient without asthma randomize .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Inclusion criterion : Patients : A minimum bilateral nasal polyp score 5 maximum score 8 ( unilateral score least 2 nostril ) despite completion prior intranasal corticosteroid ( INCS ) treatment least 8 week screen . Presence least two follow symptom prior screening : nasal blockade/obstruction/congestion nasal discharge ( anterior/posterior nasal drip ) ; facial pain/pressure ; reduction loss smell . Exclusion criterion : Patients &lt; 18 &gt; 65 year age . Sinonasal outcome test ( SNOT22 ) &lt; 7 . Patients take investigational drug prohibit therapy study within 2 month screen 5 halflives , whichever longer : Burst systemic corticosteroid within 2 month screen schedule receive systemic corticosteroid study period another condition ; Intranasal corticosteroid drop within 1 month prior screen ; Monoclonal antibody ( mAB ) immunosuppressive treatment ; Antiimmunoglobulin E ( IgE ) therapy ( omalizumab ) within 130 day Visit 1 ; .Leukotriene antagonist / modifier unless patient continuous treatment least 30 day prior Visit 1 . Patients undergone nasal surgery ( include polypectomy ) within 6 month screen 5 sinonasal surgery past maximal 2 surgery change lateral wall structure nose . Patients asthma : Forced Expiratory Volume ( FEV1 ) ≤ 60 % , asthma exacerbation require systemic ( oral and/or parenteral ) steroid treatment hospitalization &gt; 24h treatment asthma , within 3 month prior screen dose great 1000 μg fluticasone equivalent inhale corticosteroid . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>